Inhibition of brain vesicular monoamine transporter (VMAT2) enhances 1- methyl-4-phenylpyridinium neurotoxicity in vivo in rat striata

Journal of Pharmacology and Experimental Therapeutics

Volumn 293, Issue 2, 2000, Pages 336-342

  Staal, Roland G W ^a   Sonsalla, Patricia K ^a  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; 2 ETHYL 1,2,3,4,6,7 HEXAHYDRO 2 HYDROXY 3 ISOBUTYL 9,10 DIMETHOXY 11BH BENZO[A]QUINOLIZINE; CARRIER PROTEIN; DOPAMINE TRANSPORTER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; MALE; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RAT; SYNAPSE VESICLE;

1-METHYL-4-PHENYLPYRIDINIUM; 2H-BENZO(A)QUINOLIZIN-2-OL, 2-ETHYL-1,3,4,6,7,11B-HEXAHYDRO-3-ISOBUTYL-9,10-DIMETHOXY-; ANIMALS; BRAIN CHEMISTRY; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MICE; MICRODIALYSIS; NEOSTRIATUM; NEUROPEPTIDES; NEUROTOXINS; NEUROTRANSMITTER AGENTS; RATS; RATS, SPRAGUE-DAWLEY; SPECIES SPECIFICITY; SYNAPTIC VESICLES; TIME FACTORS; VESICULAR BIOGENIC AMINE TRANSPORT PROTEINS; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 0034108225     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Chiueh CC, Markey SP, Burns RS, Johannessen JN, Jacobowitz DM and Kopin IJ (1984) Neurochemical and behavioral effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in rat, guinea pig and monkey. Psychopharmacol Bull 20:548-553.
2. Daniel AJ and Reinhard JF Jr (1988) Energy-driven uptake of the neurotoxin 1-methyl-4-phenylpyridinium into chromaffin granules via the catecholamine transporter. J Biol Chem 263:5034-5036.
3. Del Zompo M, Piccardi MP, Ruiu S, Quartu M, Gessa GL and Vaccari A (1993) Selective uptake into synaptic dopamine vesicles: Possible involvement in MPTP neurotoxicity. Br J Pharmacol 109:411-414.
4. Fuller RW and Hemrick-Luecke SK (1985) Effects of amfonelic acid, α-methyltyrosine, Ro 4-1284 and haloperidol pretreatment on the depletion of striatal dopamine by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Res Commun Chem Pathol Pharmacol 48:17-25.
5. Gainetdinov RR, Fumagalli F, Wang Y-M, Jones SR, Levey AI, Miller GW and Caron MG (1998) Increased MPTP neurotoxicity in vesicular monoamine transporter 2 heterozygous knockout mice. J Neurochem 70:1973-1978.
6. Giovanni A, Sieber BA, Heikkila RE and Sonsalla PK (1994a) Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part 1: Systemic administration. J Pharmacol Exp Ther 270:1000-1007.
7. Giovanni A, Sonsalla PK and Heikkila RE (1994b) Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part 2: Central administration of 1-methyl-4-phenylpyridinium. J Pharmacol Exp Ther 270:1008-1014.
8. + toxicity encodes a vesicular amine transporter. Cell 70:539-551.
9. + toxicity. Brain Res Mol Brain Res 25:90-96.
10. Melamed E, Rosenthal J, Cohen O, Uzzan A and Globus M (1985) Amphetamine, but not reserpine, protects mice against dopaminergic neurotoxicity of MPTP. Neuropharmacology 24:923-925.
11. Moriyama Y, Amakatsu K and Futai M (1993) Uptake of the neurotoxin, 4-methyl-phenylpyridinium, into chromaffin granules and synaptic vesicles: A proton gradient drives its uptake through monoamine transporter. Arch Biochem Biophys 305:271-277.
12. Pettibone DJ, Totaro JA and Pflueger AB (1984) Tetrabenazine-induced depletion of brain monoamines: Characterization and interaction with selected antidepressants. Eur J Pharmacol 102:425-430.
13. Reinhard JF Jr, Carmichael SW and Daniels AJ (1990) Mechanisms of toxicity and cellular resistance to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 1-methyl-4-phenylpyridinium in adrenomedullary chromaffin cell cultures. J Neurochem 55:311-320.
14. Reinhard JF Jr, Daniels AJ and Humberto Viveros O (1988) Potentiation by reserpine and tetrabenazine of brain catecholamine depletions by MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) in the mouse: Evidence for subcellular sequestration as basis for cellular resistance to the toxicant. Neurosci Lett 90:349-353.
15. Reinhard JF Jr, Diliberto EJ and Daniels AJ (1989) Characterization of cellular transport, subcellular distribution and secretion of the neurotoxicant 1-methyl-4-phenylpyridinium in bovine adrenomedullary cell cultures. J Neurochem 52:1253-1259.
16. Reinhard JF Jr, Diliberto EJ, Humberto Viveros O and Daniels AJ (1987) Subcellular compartmentalization of 1-methyl-4-phenylpyridinium with catecholamines in adrenal chromaffin vesicles may explain the lack of toxicity to adrenal chromaffin cells. Proc Natl Acad Sci USA 84:8160-8164.
17. +-like neurotoxicity of a pyridinium metabolite derived from haloperidol: In vivo microdialysis and in vitro mitochondrial studies. J Pharmacol Exp Ther 268:380-387.
18. + analogue. Eur J Pharmacol 153:131-134.
19. + analogues and related charged species. J Med Chem 33:2221-2230.
20. Russo SM, Daniels AJ, Humberto Viveros O and Reinhard JF Jr (1994) Differences in the reserpine-sensitive storage in-vivo of 1-methyl-4-phenylpyridinium in rats and mice may explain differences in catecholamine toxicity to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurotoxicol Teratol 16:277-281.
21. Sibley DR (1999) New insights into dopaminergic receptor function using antisense and genetically altered animals. Annu Rev Pharmacol Toxicol 39:313-341.
22. Sonsalla PK and Nicklas WJ (1992) MPTP and animal models of Parkinson's disease, in Handbook of Parkinson's Disease (Koller WC ed) pp 319-340, Marcel Dekker, New York.
23. Sonsalla PK, Riordan DE and Heikkila RE (1991) Competitive and noncompetitive antagonists at N-methyl-D-aspartate receptors protect against methamphetamine induced dopaminergic damage in mice. J Pharmacol Exp Ther 256:506-512.
24. Sonsalla PK, Youngster SK, Kindt MV and Heikkila RE (1987) Characteristics of 1-methyl-4-(2′-methylphenyl)-1,2,3,6-tetrahydropyridine-induced neurotoxicity in the mouse. J Pharmacol Exp Ther 242:850-857.
25. + is sequestered within neurons that contain the vesicular monoamine transporter. Neuroscience 84:1177-1186.
26. Staal RGW, Hogan KA, Liang C-L, German DC and Sonsalla PK (2000) In vitro studies of striatal vesicles containing the vesicular monoamine transporter (VMAT2): Rat versus mouse differences in sequestration of 1-methyl-4-phenylpyridinium. J Pharmacol Exp Ther 293:329-335.
27. Takahashi N, Miner LL, Sora I, Ujike H, Revay RS, Kostic V, Jackson-Lewis V, Przedborski S and Uhl GR (1997) VMAT2 knockout mice: Heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion and enhanced MPTP toxicity. Proc Natl Acad Sci USA 94:9938-9943.
28. + is accumulated in the nigrostriatal dopaminergic terminals but it is not neurotoxic: A model of natural resistance to MPTP toxicity. Exp Neurol 127:54-61.